# Madrigal Pharmaceuticals, Inc.: Form 10-K/A for the period ended Dec 31, 2022

- Company: [Madrigal Pharmaceuticals, Inc.](/companies/mdgl.md) (CIK 1157601)
- Form: 10-K/A
- Filed: 2023-03-03
- Accepted by EDGAR: Mar 3, 2023, 16:17 ET
- Period: 2022-12-31
- Accession: 0001193125-23-060052
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2022-10-01 to 2022-12-31 | −$85.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | −$293.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-10-01 to 2022-12-31 | $1.7m | us-gaap:InterestExpense |
| Interest expense | 12 months, 2022-01-01 to 2022-12-31 | $4.0m | us-gaap:InterestExpense |
| Income tax | 12 months, 2022-01-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-10-01 to 2022-12-31 | −$85.9m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | −$295.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-10-01 to 2022-12-31 | −$4.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2022-01-01 to 2022-12-31 | −$17.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-10-01 to 2022-12-31 | −$4.98 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2022-01-01 to 2022-12-31 | −$17.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-10-01 to 2022-12-31 | 17,237,517 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months, 2022-01-01 to 2022-12-31 | 17,137,201 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | −$224.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $217.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-12-31 | $331.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $361.4m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $362.6m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $115.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $165.2m | us-gaap:Liabilities |
| Long-term debt | at 2022-12-31 | $49.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2022-12-31 | $197.4m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm

Filed Mar 3, 2023.
Source: SEC EDGAR, the filing index for accession 0001193125-23-060052. Last ingested by Listed: Nov 6, 2026, 18:49 ET. No prices; not investment advice.
